Latest Insider Transactions at Prelude Therapeutics Inc (PRLD)
This section provides a real-time view of insider transactions for Prelude Therapeutics Inc (PRLD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Prelude Therapeutics Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Prelude Therapeutics Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,000
-69.25%
|
$40,000
$40.04 P/Share
|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+40.92%
|
$1,000
$1.89 P/Share
|
|
Apr 07
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
828
-18.09%
|
$33,120
$40.08 P/Share
|
|
Apr 07
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Grant, award, or other acquisition
|
Direct |
828
+15.32%
|
$828
$1.89 P/Share
|
|
Apr 07
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,370
-2.78%
|
$599,430
$39.65 P/Share
|
|
Apr 07
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,370
+7.55%
|
$15,370
$1.43 P/Share
|
|
Jan 27
2021
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
10,376
+0.32%
|
$124,512
$12.85 P/Share
|
|
Sep 29
2020
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
8,332,779
+47.39%
|
-
|
|
Sep 29
2020
|
Paul A Friedman |
BUY
Conversion of derivative security
|
Direct |
448,370
+34.68%
|
-
|
|
Sep 29
2020
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1,578,947
+12.24%
|
$29,999,993
$19.0 P/Share
|
|
Sep 29
2020
|
Baker Bros. Advisors LP |
BUY
Conversion of derivative security
|
Indirect |
8,332,778
+29.9%
|
-
|
|
Sep 29
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
8,332,779
+47.39%
|
-
|
|
Sep 25
2020
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
1,236,800
+46.82%
|
$23,499,200
$19.0 P/Share
|
|
Sep 25
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,236,800
+46.82%
|
$23,499,200
$19.0 P/Share
|